Citigroup Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $760
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Citigroup analyst Eric Joseph maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $725 to $760.
Citigroup analyst Eric Joseph maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $725 to $760.